MetaCap

Artiva Biotherapeutics (ARTV) vs Compugen (CGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Artiva Biotherapeutics (ARTV) has outperformed Compugen (CGEN) over the past year, gaining 20.8% versus a gain of 20.3%. Artiva Biotherapeutics is the larger company by market cap ($186.9 million vs $174.3 million), about 1.1 times the size, while Compugen is growing revenue faster (+161.1% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARTV+20.77%CGEN+20.26%
+344%+162%-21%
Nov 21, 20251 yearNov 20, 2026
ARTV-68.50%CGEN+1.10%
+78%-9%-96%
Jul 15, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARTV versus CGEN key metrics
MetricARTVCGEN
Share price$3.78$1.84
Market cap$186.85M$174.29M
1-day change-1.31%-2.13%
YTD return-11.89%+20.26%
1-year return+20.77%+20.26%
5-year return—-59.47%
P/E ratio (TTM)—4.72
EPS (TTM)$-2.85$0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$72.76M
Revenue growth (YoY)-100.00%+161.14%
Net income (latest FY)$-83.86M$35.34M
Gross margin—87.29%
Operating margin—43.05%
Net margin—48.57%
52-week high$14.53$3.24
52-week low$2.96$1.43
Distance from 52-week high-73.98%-43.21%
Analyst consensusbuystrong_buy
Avg. price target upside+448.94%+160.87%
Average volume792.26K223.56K
Shares outstanding49.43M94.72M
Employees13475
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Compugen grew revenue faster in its latest fiscal year (+161.14% vs -100.00%).

About Artiva Biotherapeutics

ARTV stock →

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Compugen

CGEN stock →

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees

ARTV vs CGEN FAQ

Which is bigger, Artiva Biotherapeutics or Compugen?

Artiva Biotherapeutics (ARTV) is larger, with a market capitalization of $186.85M compared with $174.29M for Compugen (CGEN).

Which stock has performed better over the past year, ARTV or CGEN?

ARTV returned +20.77% over the past 12 months, compared with +20.26% for CGEN (price return, excluding dividends). Past performance does not predict future results.

Are Artiva Biotherapeutics and Compugen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons